Abcentra
Biotechnology, 1925 Century Park E, Los Angeles, California, 90067, United States, 1-10 Employees
Phone Number: 42********
Who is ABCENTRA
Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of ch...
Read More
-
Headquarters: 1925 Century Park E, Los Angeles, California, 90067, United States
-
Date Founded: 2006
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
Abcentra Org Chart and Mapping
Email
Phone
Similar Companies to Abcentra
Oncotelic
-
11-50
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Abcentra
Answer: Abcentra's headquarters are located at 1925 Century Park E, Los Angeles, California, 90067, United States
Answer: Abcentra's phone number is 42********
Answer: Abcentra's official website is https://abcentra.com
Answer: Abcentra's revenue is Under $1 Million
Answer: Abcentra's SIC: 2834
Answer: Abcentra has 1-10 employees
Answer: Abcentra is in Biotechnology
Answer: Abcentra top competitors include: Oncotelic
Answer: Abcentra contact info: Phone number: 42******** Website: https://abcentra.com
Answer: Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation. This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease. It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Abcentra is developing a potential solution for patients with cardiovascular inflammation therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease. Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline). Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors. Several additional indications are also being pursued. Abcentra has offices in Los Angeles. The Companys ownership includes world-renowned Los Angeles hospital, Cedar-Sinai. Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month